MoonLake Immunotherapeutics GAAP EPS of -$0.84 (MLTX:NASDAQ)
· seekingalpha.com
MoonLake Immunotherapeutics (MLTX) Q2 results: GAAP EPS -$0.84, $537M cash and runway to mid-2028 plus up to $400M debt facility.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...